Last reviewed · How we verify
Antiwei Granules — Competitive Intelligence Brief
phase 3
Oncology
Small molecule
Live · refreshed every 30 min
Target snapshot
Antiwei Granules (Antiwei Granules) — Tasly Pharmaceutical Group Co., Ltd. Antiwei Granules is a traditional Chinese medicine formulation that modulates immune function and inflammatory pathways to support anti-tumor activity.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Antiwei Granules TARGET | Antiwei Granules | Tasly Pharmaceutical Group Co., Ltd | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Antiwei Granules CI watch — RSS
- Antiwei Granules CI watch — Atom
- Antiwei Granules CI watch — JSON
- Antiwei Granules alone — RSS
Cite this brief
Drug Landscape (2026). Antiwei Granules — Competitive Intelligence Brief. https://druglandscape.com/ci/antiwei-granules. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing